Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study investigating efficacy and safety of Cytotect FH, nanometer filtered (BT094)

Trial Profile

Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study investigating efficacy and safety of Cytotect FH, nanometer filtered (BT094)

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Cytomegalovirus immune globulin (Primary)
  • Indications Cytomegalovirus infections; Pregnancy
  • Focus Registrational; Therapeutic Use
  • Sponsors Biotest AG
  • Most Recent Events

    • 01 Apr 2017 Status changed from recruiting to completed.
    • 30 Mar 2017 This trial has been completed in Italy.
    • 11 Mar 2017 This trial has been completed in Belgium as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top